HPV-201: A PHASE 2, RANDOMIZED, OPEN LABEL, EFFICACY STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA 2000 ALONE OR IN COMBINATION WITH IMIQUIMOD, FOR THE TREATMENT OF HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE VULVA.
Study of VGX-3100 for patients with squamous intraepithelial lesion (HSIL) of the vulva
Sponsor: Inovio Pharmaceuticals, Inc.
Enrolling: Female Patients Only
IRB Number: AAAR4755
U.S. Govt. ID: NCT03180684
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see how well an investigational new drug and study device combination work to treat women with pre-cancerous cells of the vulva caused by human papillomavirus (HPV) and,thereby avoid surgery. To participate in this study you must have high grade squamous intraepithelial lesion (HSIL) of the vulva caused by HPV types 16 or 18.
This study is closed
Investigator
Ana Tergas, MD
Do You Qualify?
Have you been diagnosed with a vulvar infection with HPV? Yes No
Do you have a high grade squamous intraepithelial lesion (HSIL) of the vulva? Yes No
Are you surgically sterile, post-menopausal, or willing to use contraceptives? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE